143782-23-4: Enzalutamide Impurity 2

It is a nonsteroidal antiandrogen that binds to the ligand-binding domain and has more affinity. It is used in the treatment of castration-resistant prostate cancer.

Additional information on CAS 143782-23-4

Catalogue No.

VE006366

CAS No.

143782-23-4

Molecular Formula

C9H36F3N2S

Molecular Weight

228.19

Parent drug

Enzalutamide

IUPAC Name

4-Isothiocyanato-2-trifluoromethylbenzonitrile

Synonyms

N/A

References

"Schrader, Andres Jan, et al. “Enzalutamide in Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel and Abiraterone.” European Urology, vol. 65, no. 1, Jan. 2014, pp. 30–36, https://doi.org/10.1016/j.eururo.2013.06.042. ?Graff, Julie N., et al. “Early Evidence of Anti-PD-1 Activity in Enzalutamide-Resistant Prostate Cancer.” Oncotarget, vol. 7, no. 33, July 2016, pp. 52810–17, https://doi.org/10.18632/oncotarget.10547. ?"

Status

In-stock

[rfq_list]

Login first to add product to RFQ List

Request a quote

143782-23-4: Enzalutamide Impurity 2

143782-23-4: Enzalutamide Impurity 2
Catalogue No.

VE006366

CAS No.

143782-23-4

Molecular Formula

C9H36F3N2S

Molecular Weight

228.19

Parent drug

Enzalutamide

IUPAC Name

4-Isothiocyanato-2-trifluoromethylbenzonitrile

Synonyms

N/A

References

"Schrader, Andres Jan, et al. “Enzalutamide in Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel and Abiraterone.” European Urology, vol. 65, no. 1, Jan. 2014, pp. 30–36, https://doi.org/10.1016/j.eururo.2013.06.042. ?Graff, Julie N., et al. “Early Evidence of Anti-PD-1 Activity in Enzalutamide-Resistant Prostate Cancer.” Oncotarget, vol. 7, no. 33, July 2016, pp. 52810–17, https://doi.org/10.18632/oncotarget.10547. ?"

Status

In-stock

ListName

Enzalutamide Impurity 2

Exclusively Supplied by Veeprho

Exclusively Supplied by Veeprho

"*" indicates required fields

Hidden
Products quotation
Name
Url
 
Hidden